Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an <i>IDH1</i>-Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report—Usage of Immune Checkpoint Inhibition in CMMRD

Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an <i>IDH1</i>-Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report—Usage of Immune Checkpoint Inhibition in CMMRD

Constitutional mismatch repair deficiency (CMMRD) is a rare autosomal recessive hereditary cancer syndrome due to biallelic germline mutation involving one of the four DNA mismatch repair genes. Here we present a case of a young female with CMMRD, homozygous for the c.2002A>G mutation in the <...

Full description

Bibliographic Details
Main Authors: Rebekah Rittberg, Craig Harlos, Heidi Rothenmund, Anirban Das, Uri Tabori, Namita Sinha, Harminder Singh, Bernie Chodirker, Christina A. Kim
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Current Oncology
Subjects:
constitutional mismatch repair deficiency
CMMRD
immunotherapy
adjuvant therapy
checkpoint inhibitors
screening
Online Access:https://www.mdpi.com/1718-7729/28/1/74

Internet

https://www.mdpi.com/1718-7729/28/1/74

Similar Items